PSA decrease during combined-modality radiotherapy predicts for treatment outcome

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 3, 2010, Pages 759-762

  Kubicek, Gregory J ^a   Naguib, Marco ^b   Redfield, Sandy ^b   Grayback, Nola ^b   Olszanski, Arthur ^b   Dawson, George ^b   Brown, Sam I ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Radiation Medicine Center   (United States)

Author keywords

Combined therapy; Outcome; Prognosis; Prostate cancer; PSA; Response

Indexed keywords

COMBINED THERAPY; OUTCOME; PROGNOSIS; PROSTATE CANCERS; PSA; RESPONSE;

DIAGNOSIS; DISEASES; ONCOLOGY;

RADIOTHERAPY;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77957195936     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.08.064     Document Type: Article

References (12)

1. A.J. Vickers, C. Savage, and M.F. O'Brien Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol 27 2009 398 403
2. A.L. Hanlon, H. Diratzouian, and G.E. Hanks Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer Int J Radiat Oncol Biol Phys 53 2002 297 303
3. P. Alcantara, A. Hanlon, and M.K. Buyyounouski Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death Cancer 109 2007 41 47
4. M.E. Ray, H.D. Thames, and L.B. Levy PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis Int J Radiat Oncol Biol Phys 64 2006 1140 1150
5. J.W. Denham, D.S. Lamb, and D. Joseph PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol 90 2009 382 388
6. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
7. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
8. J.E. Sylvester, P.D. Grimm, and J.C. Blasko 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience Int J Radiat Oncol Biol Phys 67 2007 57 64
9. G.S. Lederman, W. Cavanagh, and P.S. Albert Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy Int J Radiat Oncol Biol Phys 49 2001 1297 1303
10. A.V. D'Amico, M. Chen, and A.A. Rensah Androgen suppression and radiation vs radiation alone for prostate cancer, a randomized trial JAMA 299 2008 289 295
11. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial Lancet 360 2002 103 106
12. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978